Significant Prevalence of Diabetes to Reflect Positively on UK Metabolic Disorder Therapeutics Market

UK metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.2% during the forecast period. As per the Diabetes UK, over five million people will have diabetes in the country by 2025. Nearly 90% of the UK population with diabetes have type 2 diabetes. Nearly 2% of people with diabetes have a rarer form of diabetes. Diabetes is a form of metabolic disorders normally resulting from the ineffective response of cells to insulin (type 2 diabetes) or inadequate production of the hormone insulin (type 1 diabetes). Insulin-sensitizing drugs, including thiazolidinediones and metformin, are part of the treatment of type 2 diabetes and can also be utilized in patients suffering from metabolic syndrome. Metformin is an oral drug utilized to reduce blood glucose concentrations among patients with type-2 diabetes, primarily in patients who are obese and as well as those patients with normal renal function.

Browse the full report description UK Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Drug Therapy, Gene Therapy, Cellular Transplantation, Enzyme Replacement Therapy, and Others), By Disease (Obesity, Diabetes, Lysosomal Storage Disease, Hypercholesterolemia, and Others) and Forecast, 2020-2026 at https://www.omrglobal.com/industry-reports/uk-metabolic-disorder-therapeutics-market

Scope of the UK Metabolic Disorder Therapeutics Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Therapy and Disease
• Competitive Landscape- Bristol-Myers Squibb Co., AbbVie, Inc., Novo Nordisk A/S, Sitryx Pharmaceuticals, and AstraZeneca plc.

Recent Strategic Initiatives in the UK Metabolic Disorder Therapeutics Market

• In March 2020, AstraZeneca plc declared the collaboration with Silence Therapeutics for discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics to treat CVD, respiratory, renal, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung. 
• In March 2020, Eli Lilly and Co. declared the global licensing and research partnership with Sitryx, a biopharmaceutical company engaged in the development of therapeutics in immuno-inflammation and immuno-oncology. Under the partnership, the companies will study up to four new preclinical targets that are identified by Sitryx that could result in potential new medicines for autoimmune diseases. Lilly will make a $10 million equity investment in Sitryx and Sitryx will get an upfront payment of $50 million.

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected region/segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Metabolic Disorder Therapeutics Market-Segmentation

By Therapy

• Drug Therapy
• Gene Therapy
• Cellular Transplantation
• Enzyme Replacement Therapy
• Others

By Disease

• Obesity
• Diabetes
• Lysosomal Storage Disease
• Hypercholesterolemia
• Others